Why has the NIB share price leapt 14% in a month?

NIB shares have been in fine form recently…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has been a strong performer in recent weeks.

Since this time last month, the private health insurer's shares have risen by almost 14% to $7.89.

This leaves the NIB share price trading within a whisker of its 52-week high of $8.20.

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

Why is the NIB share price on form?

Investors have been buying the company's shares since the release of its full year results last month.

For the 12 months ended 30 June, NIB reported a 7.2% increase in revenue to $2.8 billion. This was driven by the company's Australian Residents Health Insurance (ARHI) business, which grew well ahead of industry expectations thanks to strong premium revenue growth. This was despite the company deferring the 2022 annual premium increase.

And while NIB reported a 16.6% decline in net profit to $133.8 million, this reflects investment losses of $81.8 million and was still slightly ahead of consensus estimates.

Also giving its shares a lift was management's outlook commentary. It appears cautiously optimistic on FY 2023. It said:

While wary of broader macro-economic conditions and ongoing COVID-19 threats, nib expects favourable market conditions for each of its businesses in FY23 and beyond.

Can its shares keep rising?

Unfortunately, most brokers appear to believe the NIB share price has now peaked.

The most bullish broker I'm aware of is Morgans with its hold rating and $8.36 price target. This implies potential upside of 6% for investors from current levels.

Its analysts are also expecting its shares to provide a fully franked 3.5% dividend yield in FY 2023. This stretches the total potential return to almost 10%, which isn't bad for a hold rating.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

Should I invest $10,000 into CSL shares? Yes or no

Is it time to pick up this fallen giant? Let's dig deeper into things.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »